Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a clinical trial, phase i.

Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358).

Who Took Part

Thirty-three patients with metastatic NETs were prospectively enrolled into four groups: group A (n = 6, 43 ± 12 years) administered approximately 3.7 GBq (100 mCi) 177Lu-DOTATATE as controls; group B (n = 7, 55 ± 7 years) administered approximately 1.11 GBq (30 mCi) 177Lu-DOTA-EB-TATE; group C (n = 6, 55 ± 10 years) administered approximately 1.85 GBq (50 mCi) 177Lu-DOTA-EB-TATE; group D (n = 14, 50 ± 10 years) administered approximately 3.7 GBq (100 mCi) 177Lu-DOTA-EB-TATE.

Treatment-related adverse events were graded according to the CTCAE v.5.0. 68Ga-DOTATATE PET/CT were performed at baseline and 2-3 months after treatment for response evaluation.

What Was Measured

Topics PubMed links to this paper include Evans Blue, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Positron Emission Tomography Computed Tomography and Somatostatin.

The authors tagged it with the keywords 177Lu-DOTA-EB-TATE, 177Lu-DOTATATE and Peptide receptor radionuclide therapy (PRRT).

What This Means in Plain Language

This is a clinical trial, phase i of Octreotide and Somatostatin.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (European journal of nuclear medicine and molecular imaging), a journal based in Germany.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.